Ask AI
Could it be MASH webcast

CE / CME

Could It Be MASH? Early Detection and Intervention to Improve Metabolic Outcomes

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits

Nurse Practitioners/Nurses: 1.50 Nursing contact hours

Pharmacists: 1.50 contact hours (0.15 CEUs)

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Released: July 07, 2025

Expiration: July 06, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

How often do you currently screen patients who are at risk for MALSD and MASH?

2.

A 54-yr-old patient with type 2 diabetes, obesity (BMI 33 kg/m2), and well-controlled hypertension and hyperlipidemia presents for follow-up. Screening for viral hepatitis is negative. The patient does not consume alcohol. According to current guidelines, what is the most appropriate next step in evaluating this patient?

3.

Which statement best characterizes semaglutide’s therapeutic potential in the management of MASH in patients with cardiometabolic risk factors based on the Phase 3 ESSENCE trial?

4.

A 61-yr-old patient with type 2 diabetes (A1C 7.8%), obesity (BMI 36 kg/m²), and coronary artery disease is treated with a GLP-1 receptor agonist and statin. After 18 mo, the patient has lost 8% body weight, but liver enzymes remain mildly elevated. Liver biopsy confirms MASH (NAS 5) with F2 fibrosis. Which of the following is the most appropriate next step in pharmacologic management?